AzTrials
AzTrials

DyslipidemiasNCT04186780

Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study

A study testing Shiitake cereal bar in people with Dyslipidemias, run by University of Sorocaba at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The daily change in population routine has stimulated the development of health beneficial value added products. Lentinula edodes (Shiitake) is a mushroom with high protein concentration, low lipid content, rich in fiber, minerals, vitamins, antioxidant compounds, β-glucans and chitosan. Read more about this study

Who is it for?
Ages 20 to 65 years
Conditions the study is for
Dyslipidemias
What is being tested?
Shiitake cereal bar
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
68 participants
Where
1 siteBrazil
Study dates
26 Sep 2018to 20 Sep 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; triglycerides of 150 to 200 mg/dL), were recruited, diagnosed by biochemical exams with dates recent to the day of recruitment. The be tolerant to bars ingredients and to Shiitake. Availability to attend the date and time of blood collection.

Who cannot join

  • However, some of them had diseases such as cancer, heart disease, neurodegenerative disease, diabetes, among others. These diseases could be considered as confounders of the study and some recruited people had to be excluded. Pregnant, lactating or hormone replacement women could not participate either.
  • Individuals were instructed to no change their eating habits and patterns, physical activity level or oral contraceptive use during the study, thus identifying only the effects of Shiitake added to the diet for each individual on the exposed group

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • University of Sorocaba

    Sorocaba, São Paulo, 18023-000

Other trials in Brazil

About this study

Official title: Effects of Lentinula Edodes Bar on Lipid Profile and Antioxidant Status in Borderline High Cholesterol Individuals: a Double Blind Randomized Clinical Trial

The daily change in population routine has stimulated the development of health beneficial value added products. Lentinula edodes (Shiitake) is a mushroom with high protein concentration, low lipid content, rich in fiber, minerals, vitamins, antioxidant compounds, β-glucans and chitosan. This is clinical study phase II, randomized, double-blind for analyze in the effect of eating Shiitake bars on cholesterolemia and oxidative stress levels in individuals with borderline cholesterol. Individuals with at least one of the following biochemical markers (total cholesterol, LDL or triglycerides) at the borderline level were recruited through online questionnaire. Individuals (n = 68) were randomly allocated to two groups (Group I - Shiitake free bar (n = 32); Group II - Shiitake bar (n = 36). Each individual underwent blood collection at 0, 33 and 66 days, and received an unidentified opaque bag containing the bars.Biochemical analyzes (triglycerides, total cholesterol, LDL, HDL and glucose) and oxidative stress markers (Catalase, GSH and TBARS) were performed on samples of individuals.

Read the detailed description

Study design The primary outcome of the study was cholesterolemia, as assessed by total cholesterol levels, triglycerides or low-density lipoproteins (LDL) and high-density lipoproteins (HDL). The secondary outcomes included blood glucose, Body Mass Index (BMI) and oxidative stress biomarkers.

A prospective Phase II, randomized, double blind and placebo-controlled trial was conducted from September 2018 to December 2018. The study accomplished at University of Sorocaba (UNISO), São Paulo State, Brazil. The study was approved (Annex D) by Human Research Ethics Committee from University of Sorocaba (protocol number 2.824.297), in accordance with Resolution 466/2012 of the National Health Council (BRASIL, 2012) and Research Ethics Review Committee (ERC) (WHO, 2016).

Recruitment of individuals For the recruitment of individuals, the disclosure was initiated five months before the start of Phase II trial. The research was published on the website of the University of Sorocaba (UNISO), on social media and folders distributed throughout campus containing a brief explanation about the research, inclusion and exclusion criteria, and contact of the researcher. According to the Resolution 1.170, from Anvisa (National Health Surveillance Agency), Phase II studies are not allowed with less than 12 people; however, the Agency suggests using a minimum of 24 volunteers.

Eligibility Criteria A total of 165 individuals completed the Google online survey.

  • Inclusion Criteria Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; triglycerides of 150 to 200 mg/dL), were recruited, diagnosed by biochemical exams with dates recent to the day of recruitment. The be tolerant to bars ingredients and to Shiitake. Availability to attend the date and time of blood collection.
  • Exclusion Criteria However, some of them had diseases such as cancer, heart disease, neurodegenerative disease, diabetes, among others. These diseases could be considered as confounders of the study and some recruited people had to be excluded. Pregnant, lactating or hormone replacement women could not participate either.

Individuals were instructed to no change their eating habits and patterns, physical activity level or oral contraceptive use during the study, thus identifying only the effects of Shiitake added to the diet for each individual on the exposed group.

Study Interventions. The study officially started with 68 individuals, who signed an informed term of consent. In the first (Time 0 - T0), in the second (Time 33 days - T33) and in the third (Time 66 days - T66) meetings, the subjects were submitted to nutritional assessment and anamnesis, 24-hour recall of eating habits and eating frequency.

In the first month of the study 4,100 placebo or mushroom bars were produced and in the second month the production was 3,500 bars. According to the Grotto and collaborators (2015), conducted a study evaluating different Shiitake concentrations (100, 400 and 800 mg/Kg/day) to determine the degree of toxicity in animals. Shiitake concentration of 100 mg/Kg/day has been shown to be safe. Besides, the Shiitake sweet bar formulation was approved in the sensory analysis and purchase intention in the previous study.

Randomization The individuals (68) were randomly allocated (using a table of random numbers) into 2 groups: I - Placebo group (n = 32) and II - Intervention group (n = 36). To ensure the daily recommended intake of Shiitake of 100 mg/Kg/day, each participant was weighted to determine the number of bars consumed per day.

The Individuals after nutritional assessment and blood collection, received an unidentified opaque and sealed packed containing individually vacuum bars for a period of T33 days. The patients and the data collector were blind. The bars of the intervention and placebo groups were similar in texture, flavor, aroma and appearance.

After one month, all individuals returned to the University of Sorocaba for new nutritional assessments, receiving more food bars and blood collection with the same double-blind care (T33). At the end of sixty-six days (T66), subjects returned for the last blood collection and final nutritional assessment.

Biochemical Analysis Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and glucose were analyzed by commercial kits, following the manufacturer's specifications, in the automated equipment COBAS C111 (Roche®) according to the methodologies below.

For cholesterol, 10 µL of sample and 1.0 mL of enzyme reagent were mixed at 37 ºC for 10 min for total transformation into free cholesterol, by lipoprotein lipase enzyme. The reaction involved the oxidation of free cholesterol to cholesterol-3-one and H2O2 by the cholesterol oxidase enzyme. And with the action of peroxidase on phenol with 4-aminoantipyrine formed a cherry chromogen, the color being proportional to the concentration of cholesterol.

For the determination of HDL, the serum was treated with phosphotungstate acid and magnesium chloride. So, the LDL was precipitated out from the fraction after centrifugation for 2 min at 10.000 rpm. HDL, which remained in the supernatant, was performed according to the cholesterol methodology. HDL concentration is proportional to the color. LDL was calculated by subtracting HDL cholesterol from total cholesterol.

Serum triglycerides were hydrolyzed to glycerol and free fatty acid by lipoprotein lipase. In the presence of adenosine triphosphate (ATP) and glycerol kinase, glycerol-3-phosphate was phosphorylated, which was oxidized to acetone dihydrogen phosphate and H2O2 by the glycerol phosphate oxidase. H2O2, 4-aminoantipyrine and p-chlorophenol underwent the same reaction process reported above by peroxidase in a 37 ºC water bath for 10 minutes until formation of red color.

For the blood glucose test, glucose-6-phosphate dehydrogenase oxidized glucose-6-phosphate in the presence of NADP in gluconate-6-phosphate. No other carbohydrates have been oxidized. The rate of NADPH formation during the reaction was directly proportional to the glucose concentration, being determined photometrically.

Oxidative Stress Analysis The determination of reduced glutathione (GSH) was made by quantification of reduced total thiols based. For this, 150 µL of the blood was vortexed with 100 µL 10% Triton X-100 and 100 µL 30% TCA, then centrifuged for 10 min at 4000 rpm. In the cuvette 900 µL of 1M TFK, 50 µL of supernatant, and 50 µL of 10 mM DTNB were pipetted, which reacted to form a yellow complex. The reading was taken at 412 nm in a spectrophotometer. For the calculation of concentration, the calibration curve with predefined GSH concentrations (0.005; 0.01; 0.025; 0.05; 0.1 mM) was used.

To evaluate the activity of the catalase enzyme was used, based on the decomposition of H2O2 by catalase, monitored at 240 nm. For this, the blood was diluted 60 times in 50 mM TFK. An aliquot of 20 μL was mixed to 1910 μL of the same TFK, and 70 μL of H2O2 was added, initiating the monitored reaction for three minutes. A constant of variation (κ) per minute helped in the expression of catalase enzyme (κ/min).

Thiobarbituric acid reactive substances (TBARS) were used as a biomarker of lipid peroxidation. Plasma aliquots (150 µL) were mixed with 50 µL NaOH and 50 µL Milli-Q ultrapure water (Direct 8, Millipore®) and incubated at 60 °C for 30 minutes with shaking. 250 µL of 6% H₃PO₄, 250 µL of 0.8% TBA and 100 µL of 10% SDS were added to the samples and taken to the 80 °C bath for one hour. Lipid peroxides reacted with TBA in acidic medium to form a pink compound and read in a spectrophotometer at 532 nm. To calculate the concentration of TBARS in plasma, a calibration curve of malondialdehyde, the main thiobarbituric acid reactive substance, was made (0.28; 0.56; 1.7; 3.4; 6.6 µM).

Conditions
Dyslipidemias
Being tested
Shiitake cereal bar
Keywords
Lentinula edodes, Clinical study, Cholesterolemia, Nutraceuticals
Medical subject headings
Dyslipidemias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Shiitake cereal barOther

    patients with borderline cholesterol exposed to bars with Shiitake

Study groups in NCT04186780
Study groupRoleWhat they receive
Intervention groupExperimentalIntervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
Receives: Other: Shiitake cereal bar
Placebo groupPlacebo comparatorPatients with borderline cholesterol consumed two placebo cereal bars for 66 days.
Receives: Other: Shiitake cereal bar

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Cholesterol Levels

    Total cholesterol It was analyzed by commercial kits, according to the manufacturer's specifications. The volunteers' Total Cholesterol and Triglyceride levels were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

    Measured: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

  2. Triglycerides Levels

    The triglycerides levels It was analyzed by commercial kits, according to the manufacturer's specifications. The volunteers' Total Cholesterol and Triglyceride levels were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

    Measured: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

Secondary outcomes (3)
  1. Oxidative Stress: Catalase

    The activity of the catalase enzyme was based on the decomposition of H2O2, monitored at 240 nm. A constant of variation or coefficient of variation (κ) per minute helped in the expression of catalase enzyme (κ/min). The Catalase enzyme has the responsibility to break down hydrogen peroxide. Higher scores mean a better outcome.

    Were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

    Measured: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

  2. Oxidative Stress: Reduced Glutathione (GSH)

    Reduced Glutathione was analyzed in the volunteers' samples at Time 0 (at the beginning of the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

    Measured: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

  3. Oxidative Stress: Thiobarbituric Acid Reactive Substances (TBARS)

    Reactive Substances to Thiobarbituric Acid were analyzed in the volunteers' samples at Time 0 (at the beginning of the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

    Measured: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Dec 2019
  2. Study start26 Sep 2018
  3. Primary completion1 Dec 2018
  4. Study completion20 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, randomized, double blind and placebo-controlled
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04186780
Sponsor's protocol ID
83741818.5.0000.5500
Status last verified
Oct 2020
First submitted
26 Nov 2019
Last updated
27 Oct 2020
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: After the article publication will be shared the data.

Publications

  • Aebi H. Catalase in vitro. Methods Enzymol. 1984; 105: 121-126. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82: 70-77. Friedewald, W. T.; LEVY, R. I.; Frederickson, D. S. Estimation of the concentration of low density lipoprotein in plasma without the use of the preparative ultra centrifuge. Clinical Chemistry. 1972; 18(6): 499-502 Grotto D, Gerenutti M, Souza VCO, Barbosa F Jr. Deficiency of macro and micronutrients induced by Lentinula edodes. Toxicology. 2015. 2:401-404.. Kerckhoffs DAJM, Hornstra G, Mensink RP. Cholesterol-lowering effect of β-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when β-glucan is incorporated into bread and cookies. American Journal of Clinical Nutrition. 2003; 78: 221-227. Ohkawa H, OhishI N, Yagi K. Assay for lipid peroxides in animal tissues by Thiobarbituric Acid reaction. Analyt Biochem. 1979; 95: 351-358.

Questions about this trial

What is this clinical trial studying?

A study testing Shiitake cereal bar in people with Dyslipidemias, run by University of Sorocaba at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Sep 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Cholesterol Levels (time frame: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04186780, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in